1024 CLN-978, a novel CD19/CD3/HSA T cell engager with extended serum half-life, is effective against lymphoma cells expressing very low levels of CD19

• Agapitos Patakas,
• Naveen K Mehta,
• Patrick A Baeuerle,
• Jennifer S Michaelson,
• Kristan A Meetze,
• Hannah M Findlay,
• Timothy B London

Affiliations

Agapitos Patakas

Institute of Infection, Immunity and Inflammation, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, UK

Naveen K Mehta

Cullinan Oncology Inc, Cambridge, Massachusetts, USA

Patrick A Baeuerle

Cullinan Oncology Inc, Cambridge, Massachusetts, USA

Jennifer S Michaelson

Cullinan Oncology Inc, Cambridge, Massachusetts, USA

Kristan A Meetze

1Cullinan Oncology, Inc., Cambridge, MA, USA

Hannah M Findlay

2Antibody Analytics, Motherwell, UK

Timothy B London

2Antibody Analytics, Motherwell, UK